LONDON, May 13, 2019 /PRNewswire/ -- Smith & Nephew
(LSE: SN, NYSE: SNN), the global medical technology business, today
announces the U.S. launch of the WEREWOLF™ FLOW 90 Wand with
FLOW~IQ™ Technology. Designed for use in the shoulder but indicated
for use on all soft tissue types, the 90-degree wand was developed
to use with the WEREWOLF COBLATION System.
Smith & Nephew's patented COBLATION technology has been
shown to deliver faster patient recovery3 and better
long-term patient outcomes1,2 compared to mechanical
debridement in the knee according to a level 1 randomized
controlled trial carried out over 10 years.
"FLOW 90 was fantastic. It excels at rapid bulk tissue removal
while remaining very precise. FLOW 90's triangular tip also enables
you to do excellent dissection," commented Dr. Scott Trenhaile, Assistant Professor,
Rush University Medical Center. "This
combination of speed, control and dissection is unmatched by any
other radio-frequency device, and is an exciting addition to the
Smith & Nephew portfolio."
"We believe the FLOW 90 is quite simply the best wand Smith
& Nephew has ever made and we're confident our customers will
feel the same way once they experience it and see the results,"
said Brad Cannon, President of
Sports Medicine & ENT, Smith & Nephew. "Our unique
COBLATION technology continues to be the industry leading choice
for arthroscopy and the FLOW 90 Wand is just the latest exciting
addition to our growing portfolio of comprehensive shoulder
solutions."
COBLATION technology creates and applies an energy field called
'glow discharge plasma', which acts to ablate molecules in the
tissue. COBLATION technology operates at lower temperatures than
other radio frequency-based technologies,6 allowing for
precise removal of soft tissue with minimal damage to untargeted
tissue.7
For more information visit:
www.werewolfcoblation.com
References
- Spahn, G, Klinger HM, Mückley T, Hofmann GO. Four-Year Results
From a Randomized Controlled Study of Knee Chondroplasty With
Concomitant Medial Meniscectomy: Mechanical Debridement Versus
Radiofrequency Chondroplasty. Arthroscopy: The Journal of
Arthroscopic and Related Surgery, Vol 26, No 9 (September, Suppl
1), 2010: pp S73-S80. DOI 10.1016/j.arthro.2010.02.030.
- Spahn G, Hofmann GO, von Engelhardt LV. Mechanical Debridement
Versus Radiofrequency in Knee Chondroplasty with Concomitant Medial
Meniscectomy: 10-year Results from a Randomized Controlled Study.
Knee Surg Sports Traumatol Arthrosc. DOI 10.1007/s00167-015-3810-6.
Epub 2015 October 1.
- Spahn G, Kahl E, Mückley T, Hofmann GO, Klinger HM.
Arthroscopic Knee Chondroplasty using a Bipolar
Radiofrequency-based Device Compared to Mechanical Shaver: Results
of a Prospective, Randomized, Controlled Study. Knee Surg Sports
Traumatol Arthrosc (2008) 16:565–573. DOI
10.1007/s00167-008-0506-1. Epub 2008 March
8.
- Gharaibeh, M., Szomor A., Chen D.B. & MacDessi, S.J. 2017.
Cartilage. A Retrospective Study Assessing Safety and Efficacy of
Bipolar Radiofrequency Ablation for Knee Chondral Lesions.
Cartilage. 2017 Apr 1. [Epub ahead of
print]
- Voloshin, I., Morse K.R., Allred, C.D., Bissell, S.A., Maloney,
M.D. & DeHaven, K.E. Arthroscopic evaluation of radiofrequency
chondroplasty of the knee. American Journal of Sports Medicine.
2007; 35: 1702-1707.
- Woloszko J, Kwende M, Stalder K. COBLATION in
Otolaryngology. Proceedings of the SPIE. 2003; 341:
341-352.
- Amiel D, Ball S, Tasto J. Chondrocyte Viability and Metabolic
Activity After Treatment of Bovine Articular Cartilage With Bipolar
Radiofrequency: An In Vitro Study. Arthroscopy. 2004; 5(20):
503-510
About Smith & Nephew
Smith & Nephew is a portfolio medical technology business
with leadership positions in Orthopaedics, Advanced Wound
Management and Sports Medicine. Smith & Nephew has more than
16,000 employees and a presence in more than 100 countries. Annual
sales in 2018 were $4.9 billion.
Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
corporate website www.smith-nephew.com and follow us
on Twitter, LinkedIn or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith & Nephew.
Certain marks registered US Patent and Trademark Office.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/smith--nephew-launches-new-flow-90-wand-at-isakos-joining-its-innovative-collection-of-coblation-technology-and-shoulder-repair-portfolios-300848596.html
SOURCE Smith & Nephew